[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-cabg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-cabg":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100613970",false,"NCT07273513","\"Smart Family Doctor\" Assisted Comprehensive Management of Secondary Prevention Among Post Revascularization Patients","SMART II","Inclusion Criteria:\n\n* Age 18-80 years.\n* Underwent CABG or PCI more than 3 months prior and have concurrent hypertension, diabetes, and dyslipidemia.\n* At least one of the following criteria is meet:\n* Systolic blood pressure no less than 130 mmHg or diastolic blood pressure no less than 80 mmHg\n* HbA1c no less than 7%\n* LDL-C no less than 1.4 mmol\u002FL\n* Signed informed consent.\n\nExclusion Criteria:\n\n* History of heart failure or severe arrhythmias.\n* Presence of other severe underlying conditions such as cancer or liver and kidney insufficiency.\n* Pregnancy, lactation, or plans for pregnancy within the next year.\n* Cognitive, communication impairments, or limitations in daily activities.\n* Unable to use smartphone.","ALL","18 Years","80 Years",{"count":19,"type":20},951,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the effect of an AI-assisted \"Smart family doctor\" digital health management tool on improving the control rates of hypertension, diabetes, and dyslipidemia in post-revascularization patients. A randomized controlled trial design will be used, involving approximately 10-20 hospitals and 951 participants. Eligible participants are adults aged between 18 and 80 years, post-CABG or post-PCI patients with hypertension, diabetes, and dyslipidemia.",[26,27,28,29,30],"Hypertension","Diabete Mellitus","Hyperlipidemia","Post PCI","Post CABG",[32,33,34,35,36],"smartphone","AI-assisted","Revascularization management","metabolic management","Smart family doctor","NOT_YET_RECRUITING","2025-12-10",{"date":40,"type":41},"2025-12-18","ACTUAL",{"date":43,"type":20},"2026-01-15",{"date":45,"type":20},"2027-01-15",{"name":47,"class":48},"China National Center for Cardiovascular Diseases","OTHER_GOV",""]